

(5)

Atty. Dkt. No. 018733-0987

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicant: **Gary L. GRIFFITHS et al.**Title: **TARGETED  
COMBINATION-  
IMMUNOTHERAPY OF  
CANCER**Appl. No.: **09/597,580**Filing Date: **08/20/2000**Examiner: **Dameron L. Jones**Art Unit: **1616**Confirmation No.: **5842****Match and Return****AMENDMENT TRANSMITTAL**

Commissioner for Patents  
 Box NON-FEE AMENDMENT  
 Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

Small Entity statement is enclosed.

The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	52	—	52	—	0 x \$18.00 — \$0.00
Independents:	3	—	3	—	0 x \$84.00 — \$0.00
First presentation of any Multiple Dependent Claims:				+	\$280.00 — \$0.00
<b>CLAIMS FEE TOTAL:</b>					<b>\$0.00</b>

Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

Atty. Dkt. No. 013733-0987

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$410.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$930.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,450.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,970.00	\$0.00
		<b>EXTENSION FEE TOTAL:</b>	<b>\$0.00</b>
		<b>CLAIMS AND EXTENSION FEE TOTAL:</b>	<b>\$0.00</b>
<input checked="" type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
		<b>TOTAL FEE:</b>	<b>\$0.00</b>

Please charge Deposit Account No. 19-0741 in the amount of \$\_\_\_\_\_. A duplicate copy of this transmittal is enclosed.

A check in the amount of \$\_\_\_\_\_. is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date Jan. 15, 2003

By Stephen B. Maebius

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5143  
Telephone: (202) 672-5589  
Facsimile: (202) 672-5399

Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge deposit account No. 19-0741 for any such fees; and applicants hereby petition for any needed extension of time.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Gary L. GRIFFITHS et al.  
Title: TARGETED COMBINATION IMMUNOTHERAPY OF CANCER  
AND INFECTIOUS DISEASE  
Appl. No.: 09/597,580  
Filing Date: 06/20/2000  
Examiner: Dameron L. JONES  
Art Unit: 1616  
Confirmation No.: 5842

JM  
P. JONES  
19/C  
3/25/03  
CLERK

**AMENDMENT UNDER 37 C.F.R. § 1.312**

Commissioner for Patents  
Washington, D.C. 20231

**Match and Return**

Sir:

This amendment is filed after the Notice of Allowance dated October 28, 2002 and with the payment of the base issue fee in the above-identified application. This amendment corrects a typographical error in claim 53.

Kindly amend the application as follows:

**IN THE CLAIMS:**

53. (Amended) The composition of claim 11, wherein said hormones and antagonists are selected from the group consisting of adrenocorticosteroids, progestins, estrogens, and androgens.